Comparative Pharmacology
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus PROLIXIN DECANOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus PROLIXIN DECANOATE.
MOLINDONE HYDROCHLORIDE vs PROLIXIN DECANOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic that blocks dopamine D1 and D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways, with higher affinity for D2 receptors. It also exhibits alpha-adrenergic blocking and anticholinergic activity.
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
Fluphenazine decanoate initial dose 12.5-25 mg IM or SC every 1-4 weeks; maintenance dose 12.5-50 mg every 2-4 weeks.
None Documented
None Documented
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Terminal elimination half-life approximately 14 days (range 6-25 days) after intramuscular injection, reflecting slow release from the oily depot; allows for every 2-4 week dosing.
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Renal (approximately 50% as conjugated metabolites, <1% unchanged) and fecal (approximately 30%, primarily via bile).
Category C
Category C
Antipsychotic
Antipsychotic